Abstract

Parkinson’s disease is the second most prevalent neurodegenerative disorder in the Western world. It is estimated that the neuronal loss related to Parkinson’s disease precedes the clinical diagnosis by more than 10 years (prodromal phase) which leads to a subtle decline that translates into non-specific clinical signs and symptoms. By leveraging diffusion magnetic resonance imaging brain (MRI) data evaluated longitudinally, at least at two different time points, we have the opportunity of detecting and measuring brain changes early on in the neurodegenerative process, thereby allowing early detection and monitoring that can enable development and testing of disease modifying therapies. In this study, we were able to define a longitudinal degenerative Parkinson’s disease progression pattern using diffusion magnetic resonance imaging connectivity information. Such pattern was discovered using a de novo early Parkinson’s disease cohort (n = 21), and a cohort of Controls (n = 30). Afterward, it was tested in a cohort at high risk of being in the Parkinson’s disease prodromal phase (n = 16). This progression pattern was numerically quantified with a longitudinal brain connectome progression score. This score is generated by an interpretable machine learning (ML) algorithm trained, with cross-validation, on the longitudinal connectivity information of Parkinson’s disease and Control groups computed on a nigrostriatal pathway-specific parcellation atlas. Experiments indicated that the longitudinal brain connectome progression score was able to discriminate between the progression of Parkinson’s disease and Control groups with an area under the receiver operating curve of 0.89 [confidence interval (CI): 0.81–0.96] and discriminate the progression of the High Risk Prodromal and Control groups with an area under the curve of 0.76 [CI: 0.66–0.92]. In these same subjects, common motor and cognitive clinical scores used in Parkinson’s disease research showed little or no discriminative ability when evaluated longitudinally. Results suggest that it is possible to quantify neurodegenerative patterns of progression in the prodromal phase with longitudinal diffusion magnetic resonance imaging connectivity data and use these image-based patterns as progression markers for neurodegeneration.

Highlights

  • As the world demography changes and life spans increase, the population suffering from neurodegenerative diseases for which age is an unmodifiable risk factor, will undoubtedly increase

  • The Parkinson’s disease cohort are de novo subjects having a diagnosis of Parkinson’s disease by the United Kingdom brain bank criteria for 2 years or less, Hoehn and Yahr stage of I or II at baseline (H&Y; Hoehn and Yahr, 1998), not expected to require Parkinson’s disease medication within 6 months from baseline and confirmation of dopamine transporter deficit by dopamine transporter (DAT) scan or VMAT-2 PET; the PROD cohort are subjects that meet criteria of REM Sleep Behavior Disorder (RBD) according to the International Classification of Sleep Disorders – 3rd Edition and/or hyposmia confirmed with The University of Pennsylvania Smell Identification Test (UPSIT) score equal to or below the 10th percentile by age and gender

  • We started from all the PROD subjects available having at least a diffusion magnetic resonance imaging brain (MRI) acquisition (n = 21)

Read more

Summary

Introduction

As the world demography changes and life spans increase, the population suffering from neurodegenerative diseases for which age is an unmodifiable risk factor, will undoubtedly increase. The prevalence of Parkinson’s disease (PD), the second most frequent neurodegenerative disorder, is likely to double by 2040 in the United States alone (Kowal et al, 2013). It is estimated that Parkinson’s disease neuronal loss precedes the clinical diagnosis for more than 10 years (prodromal period) (de la FuenteFernández, 2013), during which time there is a subtle motor decline and a constellation of non-motor signs that cannot be detected with the current standard of care (Hughes et al, 1992; Braak et al, 2005; Hawkes, 2008; Rolheiser et al, 2011; Postuma et al, 2012). There are no proven methodologies for identifying subjects in the prodromal phase or to track their progression. This significantly hinders the ability to develop, test and eventually deploy disease-modifying therapies

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call